126 related articles for article (PubMed ID: 37652522)
1. Cetuximab Plus Concurrent Radiotherapy in Patients With Nasopharyngeal Carcinoma.
Yamauchi M; Sato Y; Ishida T; Minesaki A; Shimazaki E; Kuratomi Y
In Vivo; 2023; 37(5):2224-2228. PubMed ID: 37652522
[TBL] [Abstract][Full Text] [Related]
2. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.
Niu X; Hu C; Kong L
J Cancer Res Clin Oncol; 2013 Jun; 139(6):1063-71. PubMed ID: 23525586
[TBL] [Abstract][Full Text] [Related]
3. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
4. Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case-control study.
Li Y; Chen QY; Tang LQ; Liu LT; Guo SS; Guo L; Mo HY; Chen MY; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Shao JY; Sun Y; Tan J; Chen S; Ma J; Zhao C; Mai HQ
BMC Cancer; 2017 Aug; 17(1):567. PubMed ID: 28836950
[TBL] [Abstract][Full Text] [Related]
5. Real-world clinical outcomes in Japanese patients with locally advanced squamous cell carcinoma of the head and neck treated with radiotherapy plus cetuximab: a prospective observational study (JROSG12-2).
Ota Y; Kodaira T; Fujii H; Shimokawa M; Yokota T; Nakashima T; Monden N; Homma A; Ueda S; Akimoto T
Int J Clin Oncol; 2022 Nov; 27(11):1675-1683. PubMed ID: 36001247
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of induction chemotherapy with vinorelbine plus cisplatin (NP) or docetaxel plus cisplatin (TP) combined with concurrent chemoradiotherapy for patients with locally advanced nasopharyngeal carcinoma].
Han SH; Yu L; Zhang Z; Zhang PJ; Song HP; Guo CY
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):623-6. PubMed ID: 24314223
[TBL] [Abstract][Full Text] [Related]
7. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients.
Nakahara S; Hanamoto A; Seo Y; Miyaguchi S; Yamamoto Y; Tomiyama Y; Yoshii T; Takenaka Y; Yoshioka Y; Isohashi F; Ogawa K; Inohara H
Jpn J Clin Oncol; 2016 Oct; 46(10):903-910. PubMed ID: 27474126
[TBL] [Abstract][Full Text] [Related]
8. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan.
Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008
[TBL] [Abstract][Full Text] [Related]
9. Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
Xu T; Liu Y; Dou S; Li F; Guan X; Zhu G
Oral Oncol; 2015 Sep; 51(9):875-9. PubMed ID: 26163437
[TBL] [Abstract][Full Text] [Related]
10. A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma.
Zhang X; Du L; Zhao F; Wang Q; Yang S; Ma L
Int J Biol Sci; 2016; 12(4):446-53. PubMed ID: 27019628
[TBL] [Abstract][Full Text] [Related]
11. Induction plus adjuvant chemotherapy, combined treatment with nimotuzumab, and intensity-modulated radiation therapy for N3 stage nasopharyngeal carcinoma: A pilot study.
Zhou L; Lin J; Chen J; Zhang S
J Cancer Res Ther; 2021 Dec; 17(7):1730-1735. PubMed ID: 35381746
[TBL] [Abstract][Full Text] [Related]
12. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients.
Hirasawa K; Okamoto I; Motohashi R; Sato H; Takase S; Agata A; Takeda A; Tsukahara K
Auris Nasus Larynx; 2017 Dec; 44(6):724-728. PubMed ID: 28237712
[TBL] [Abstract][Full Text] [Related]
13. [Concurrent chemoradiotherapy followed by adjuvant chemotherapy for stage III-IVa nasopharyngeal carcinoma].
Hu QY; Liu P; Wang L; Fu ZF
Ai Zheng; 2007 Apr; 26(4):394-7. PubMed ID: 17430659
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Kong L; Zhang YW; Hu CS; Guo Y
Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma.
Zhong YH; Dai J; Wang XY; Xie CH; Chen G; Zeng L; Zhou YF
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1577-83. PubMed ID: 23549883
[TBL] [Abstract][Full Text] [Related]
17. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
Tang LL; Guo R; Zhang N; Deng B; Chen L; Cheng ZB; Huang J; Hu WH; Huang SH; Luo WJ; Liang JH; Zheng YM; Zhang F; Mao YP; Li WF; Zhou GQ; Liu X; Chen YP; Xu C; Lin L; Liu Q; Du XJ; Zhang Y; Sun Y; Ma J
JAMA; 2022 Aug; 328(8):728-736. PubMed ID: 35997729
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma.
Feng HX; Guo SP; Li GR; Zhong WH; Chen L; Huang LR; Qin HY
Med Oncol; 2014 Sep; 31(9):170. PubMed ID: 25119503
[TBL] [Abstract][Full Text] [Related]
19. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: A multicenter, open-label, randomized controlled trial.
Liang L; Liu Z; Zhu H; Wang H; Wei Y; Ning X; Shi Z; Jiang L; Lin Z; Yan H; Wang R; Hu K
Cancer; 2022 Apr; 128(7):1467-1474. PubMed ID: 34910297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]